INTRODUCTION

The main cause of death in diabetic patients is cardiovascular disease. It has been reported that two out of every three diabetic patients die of heart failure, myocardial infarction and stroke [1]. Loss of kidney function is a major risk factor for cardiovascular disease [2,3]. Renal dysfunction due to diabetic nephropathy increases the risk of cardiovascular disease, which is the main cause of death in diabetic patients [4]. The current gold standard for estimation of renal function is the glomerular filtration rate (GFR), but this test is time consuming and expensive, thus precluding its routine use in clinical settings. Estimation of GFR from prediction equations based on serum creatinine measurements (Cockcroft-Gault or Modification of Diet in Renal Disease equations) is imperfect [5]. Therefore, researchers have tried to develop more accurate markers for renal function, and serum cystatin C has recently emerged as a target of interest.

Cystatin C is a cysteine protease inhibitor with a low-molecular weight (13 kD) that is produced by all nucleated cells at a constant rate. It is freely filtered across the glomerular membrane and is almost completely reabsorbed and catabolized in proximal renal tubular cells [6]. Unlike serum creatinine, cystatin C is not influenced by age, sex, muscle mass, exercise or diet. Therefore, the serum cystatin C level is a superior marker for the evaluation of renal function compared to other markers such as serum creatinine or creatinine clearance [7-9]. Serum cystatin C level has also been reported to have a higher sensitivity and accuracy than serum creatinine for detecting changes in GFR in diabetic patients [10,11].

It has been reported that serum cystatin C level is a stronger predictor of mortality and cardiovascular events than serum creatinine or estimated GFR in elderly patients with chronic renal disease or coronary heart disease [12-14]. However, few data exist on the relationship between serum cystatin C level and cardiovascular disease in diabetic patients with or without diabetic nephropathy. The aim of the present study was to evaluate whether serum cystatin C level is associated with coronary artery disease (CAD) independent of diabetic nephropathy.

METHODS

Study design

This was a retrospective case-control study. Among 460 diabetic patients who visited the Diabetes Center of Asan Medical Center for evaluation of micro- and macrovascular complications, 38 diabetic patients with CAD were included in the study. The control group consisted of 38 diabetic patients who were matched by age, sex, and presence/absence of diabetic nephropathy. After obtaining written informed consent from each individual and the approval of our institutional review committee, we obtained blood samples from each patient and recorded patient age, sex, blood pressure, duration of diabetes, and other clinical information.

Definition of coronary artery diseases

Patients with CAD (CAD group) were defined as patients who have a past history of stable angina, acute coronary syndrome (myocardial infarction and unstable angina), coronary bypass surgery or percutaneous coronary intervention. Patients without CAD (non-CAD group) were defined as having no past history of coronary artery disease or suggestive symptoms with a normal electrocardiogram.

Definition of diabetic nephropathy

Urinary albumin excretion (UAE) was measured by radioimmunoassay from timed overnight urine collections. Individuals were considered normoalbuminuric if the UAE value was under 20 µg/min. Microalbuminuria was defined as UAE 20 to 200 µg/min on at least two of the three measurements. Overt proteinuria was defined as UAE > 200 µg/min. Azotemia was defined as serum creatinine > 1.5 mg/dL or estimated GFR < 60 mL/min/1.73 m².

Analysis of serum cystatin C

The serum cystatin C level in the stored plasma samples was measured by particle-enhanced immunonephelometry using the N Latex Cystatin C kit (Dade Behring, Marburg, Germany) and the level was expressed as mg/dL.

Statistical analysis

Values are expressed as the means ± standard deviation. Statistical analysis was performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA). The paired t-test or Wilcoxon signedrank test and McNemar's test were used to assess differences in continuous variables and categorized variables, respectively. The differences in serum cystatin C levels according to the number of stenotic vessels in 38 diabetic patients with CAD were analyzed by Kruskal-Wallis analysis. Conditional logistic regression analysis was performed to determine the risk factor for CAD. Differences were classified as significant at P < 0.05.

RESULTS

Clinical characteristics of CAD and non-CAD subjects in diabetic patients

Clinical characteristics between 38 CAD patients and 38 non-CAD patients are shown in Table 1. The mean age of the two groups was 61.7 years and most patients had type 2 diabetes mellitus, except for one patient who had type 1 diabetes mellitus. The mean duration of diabetes did not differ between the CAD and non-CAD groups (15.21 ± 8.09 years vs. 14.82 ± 7.83 years, respectively, P = 0.733). The prevalence of diabetic retinopathy, diabetic neuropathy and hypertension did not differ between the two groups. Serum cystatin C level did not differ between the CAD and non-CAD groups (0.87 ± 0.44 mg/L vs. 0.84 ± 0.32 mg/L, respectively, P = 0.794).

Serum cystatin C level based on diabetic nephropathy in CAD and non-CAD group

The two groups were divided into three subgroups each, i.e., normoalbuminuric, microalbuminuria, overt proteinuria and azotemia groups, and the serum cystatin C level was compared among the groups. The serum cystatin C level increased with a worsening of diabetic nephropathy, but did not differ between the CAD and non-CAD groups (Table 2).

Serum cystatin C level according to the number of stenotic vessels in the CAD group

When the CAD group was divided into three subgroups, i.e., one vessel disease, two vessel disease, and three vessel disease, the serum cystatin C level according to the number of stenotic vessels did not show significant differences (Table 3).

Risk factor for CAD

Conditional univariate logistic regression analysis was performed to determine the risk factors for CAD. Neither cystatin C level nor HbA1C, duration of diabetes, serum creatinine, or hypertension was associated with CAD (Table 4).

DISCUSSION

In this study, we did not detect a relationship between serum cystatin C level and CAD in diabetic patients. This result is in conflict with results from previous studies, which reported that cystatin C level is a predictor of cardiovascular disease and mortality. In our study, we selected diabetic patients with and without CAD who were matched for age, sex and presence of diabetic nephropathy. Serum cystatin C level was higher in patients with diabetic nephropathy, but no differences were found between CAD and non-CAD groups. Therefore serum cystatin C level is associated with diabetic nephropathy, but is not associated with CAD.

Cystatin C, a cationic low-molecular weight protein (13 kD), is freely filtered across the glomerular membrane and is almost completely reabsorbed in proximal renal tubular cells [15]. Unlike serum creatinine, for which the serum concentration is strongly affected by muscle mass, cystatin C is produced by all nucleated cells at a constant rate and its serum level is relatively unaffected by age, sex, body composition, diet, and exercise [16,17]. Based on these characteristics, cystatin C has been extensively studied as a potential alternative for creatinine as a serum marker of kidney function. Many studies have been shown that serum cystatin C level is superior to serum creatinine as an estimate for GFR, and can be used to detect mild renal function impairment and rapid changes in GFR. Also, cystatin C level is superior to creatinine for the estimation of GFR under conditions in which there is an altered creatinine production [18]. It has long been recognized that renal dysfunction is an important risk factor of cardiovascular disease. Many researchers have tried to identify more accurate markers for renal function and serum cystatin C level has drawn recent attention.

Serum cystatin C levels in patients with chronic renal disease are associated with cardiovascular disease mortality and all cause mortality [19], and were shown to predict cardiovascular death, myocardial infarction and stroke in a prospective cohort of adults aged ≥ 65 years [12]. Serum cystatin C in patients with CAD is associated with total mortality, cardiovascular events and heart failure [20], and was also found to be associated with total mortality in a follow up study of patients with acute coronary syndrome [13]. Moreover, a study in elderly patients without chronic renal disease showed that serum cystatin C was associated with the risk of total mortality, cardiovascular disease mortality, myocardial infarction and stroke [21]. In a study of an adult population without proteinuria and with GFR > 60 mL/min/1.73 m², serum cystatin C level was associated with increased incidence of cardiovascular disease [22]. Finally, the serum cystatin C level in patients with CAD who had normal or mildly reduced kidney function predicted cardiovascular disease mortality after adjustment for potential confounders, including classical risk factors and N-terminal pro B-type natriuretic peptide (NT-pro BNP) [14].

The mechanism by which serum cystatin C level and cardiovascular disease are related has not been established. However, depending on the association of serum cystatin C and hsCRP levels, cystatin C level was suggested to be associated with inflammation [12,23]. It was also proposed that cystatin C has a direct effect on atherosclerosis and inflammation [24]. Cystatin C is the most potent endogenous inhibitor of cysteine proteinases such as cathepsins, elastase and papain. Because cysteine proteinases have a prominent role in protein catabolism and the cleavage of membrane and extracellular matrix proteins, cystatin C probably has a central regulatory function in the extracellular compartment. Consequently, imbalance between the proteases and inhibitors may affect the cardiovascular system. In addition, cystatin C is probably involved in the regulation of inflammatory processes, where it inhibits polymorphonuclear cell chemotaxis, O₂-release and phagocytosis [25]. Because cystatin C is an inhibitor of cathepsin, its concentration increases as compensation for elevated elastolytic activity [26]. Cytokines related with atherosclerosis stimulate the production of cathepsin and increase the cystatin C concentration. Despite the above mentioned mechanisms, there is no evidence that elevation of serum cystatin C in actual clinical conditions is associated with cardiovascular disease by inflammation.

Our results are in apparent contrast with those of previous studies. In diabetic patients, most previous studies have primarily focused the relationship with impaired renal function. A recent study reported a statistically important relationship between serum cystatin C level and CAD in type 1 diabetic patients, but this study had some limitations [27]; surrogate markers of CAD were used, rather than CAD events or death. More importantly, this study was limited because they did not consider UAE. In another study, serum cystatin C level predicted the elevation of hsCRP [28]. However, as stated above, this result also did not show a direct association with cardiovascular disease and cystatin C. A recent study showing that serum cystatin C is associated with the risk for cardiovascular disease in patients with type 2 diabetes mellitus [29] was also limited because it assessed estimated risk instead of recording cardiovascular events.

In our study, we did not find an association between serum cystatin C level and CAD. Several other studies have reported similar results. In patients without CAD, serum cystatin C predicted chronic renal disease, but not CAD [30]. In a study of middle-aged subjects, carotid atherosclerosis was found to be associated with microalbuminuria, but not serum cystatin C level [11]. Therefore, in most studies reporting serum cystatin C as a predictor of the risk for cardiovascular disease, it is not clear whether cardiovascular disease was a direct effect of elevated level of cystatin C or indirect effect of deterioration of renal function.

In conclusion, our results suggest that serum cystatin C levels are useful to assess renal function, but that they are not a suitable marker for CAD. However, our study is limited in that it is a retrospective study with a small sample size. Further prospective studies with larger sample sizes are needed to evaluate the relationship between serum cystatin C and cardiovascular disease.

REFERENCES

• 1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234. ArticlePubMed
• 2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295. ArticlePubMed
• 3. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129. ArticlePubMed
• 4. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med 2008;8:533-543. ArticlePubMed
• 5. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483. ArticlePubMed
• 6. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992;38(Suppl 1):S20-S27. PubMed
• 7. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function: a review. Clin Chem Lab Med 1999;37:389-395. ArticlePubMed
• 8. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226. ArticlePubMed
• 9. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707. ArticlePubMedPDF
• 10. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002;61:1453-1461. ArticlePubMed
• 11. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funabiki K, Fukui M, Horikoshi S, Shirato I, Saito K, Tomino Y. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224-226. ArticlePubMedPDF
• 12. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060. ArticlePubMed
• 13. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-2348. ArticlePubMed
• 14. Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, Bickel C, Tzikas S, Peetz D, Lackner KJ, Tiret L, Munzel TF, Blankenberg S, Schnabel RB. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Athero-Gene study. Eur Heart J 2009;30:314-320. ArticlePubMed
• 15. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996;56:409-414. ArticlePubMed
• 16. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene. Biochem J 1990;268:287-294. ArticlePubMedPMCPDF
• 17. Price CP, Finney H. Developments in the assessment of glomerular filtration rate. Clin Chim Acta 2000;297:55-66. ArticlePubMed
• 18. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998;101:875-881. ArticlePubMedPDF
• 19. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007;147:19-27. ArticlePubMed
• 20. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study. Circulation 2007;115:173-179. ArticlePubMed
• 21. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246. ArticlePubMed
• 22. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008;102:54-57. ArticlePubMed
• 23. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421. ArticlePubMed
• 24. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990;188:16-22. ArticlePubMed
• 25. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006;21:1223-1230. ArticlePubMedPDF
• 26. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932-1943. ArticlePubMedPDF
• 27. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007;56:2774-2779. ArticlePubMedPDF
• 28. Ogawa Y, Goto T, Tamasawa N, Matsui J, Tando Y, Sugimoto K, Tomotsune K, Kimura M, Yasujima M, Suda T. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Diabetes Res Clin Pract 2008;79:357-361. PubMed
• 29. Lee SH, Lee KW, Kim ES, Park YR, Kim HS, Park SA, Kang MJ, Ahn YB, Yoon KH, Cha BY, Son HY, Kwon HS. Cystatin C is a valuable marker for predicting future cardiovascular disease in type 2 diabetic patients. Korean Diabetes J 2008;32:488-497.Article
• 30. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P. PRIME Study Group. Plasma cystatin-C and development of coronary heart disease: The PRIME study. Atherosclerosis 2006;185:375-380. ArticlePubMed

Table 1

Baseline characteristics of the diabetic patients included in this study

Data are presented as means ± standard deviation.

CAD, coronary artery disease; M, male; F, female; DM, diabetes mellitus; HTN, hypertension.

Table 2

Serum cystatin C level among subgroups of diabetic nephropathy

Data are presented as means ± standard deviation.

CAD, coronary artery disease.

Table 3

Comparisons of serum cystatin C levels according to the number of stenotic vessels in 38 diabetic patients with CAD

Data are presented as means ± standard deviation.

CAD, coronary artery disease.

Table 4

Factors associated with coronary artery disease based on conditional univariate logistic regression analysis

CI, confidence interval; HTN, hypertension.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Higher Levels of Cystatin C in HIV/AIDS Patients with Metabolic Syndrome
  Gordana Dragović, Danica Srdić, Khawla Al Musalhi, Ivan Soldatović, Jovana Kušić, Djordje Jevtović, Devaki Nair
  Basic & Clinical Pharmacology & Toxicology.2018; 122(4): 396.     CrossRef
• The association between serum cystatin C and carotid intima–media thickness in metabolic syndrome patients with normal estimated glomerular filtration rate
  Rong Huang, Jingli Gu, Qin Cao, Jiahua Ma, Weiwei Gu, Zhuping Fan
  Clinica Chimica Acta.2015; 448: 170.     CrossRef
• Association of plasma cystatin C levels with angiographically documented coronary artery disease in patients of Indian origin
  Aditya Batra, Aditya Kapoor, R.K. Sharma, Nitin Agrawal, Archana Sinha, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin K. Goel
  Journal of Cardiology.2012; 59(2): 182.     CrossRef
• Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate
  Xie Qing, Wang Furong, Liu Yunxia, Zhang Jian, Wang Xuping, Gao Ling
  Cardiovascular Diabetology.2012;[Epub]     CrossRef
• Response: Lack of Association between Serum Cystatin C Levels and Coronary Artery Disease in Diabetic Patients (Korean Diabetes J 2010;34:95-100)
  Eun Hee Kim, Ki-Up Lee
  Korean Diabetes Journal.2010; 34(3): 209.     CrossRef
• Serum Cystatin C as a Biomarker for Predicting Coronary Artery Disease in Diabetes
  Jee-Young Oh
  Korean Diabetes Journal.2010; 34(2): 84.     CrossRef
• Letter: Lack of Association between Serum Cystatin C Levels and Coronary Artery Disease in Diabetic Patients (Korean Diabetes J 2010;34:95-100)
  Kyu-Chang Won
  Korean Diabetes Journal.2010; 34(3): 207.     CrossRef

About this article

Kim EH, Yu JH, Lee SA, Kim EY, Kim WG, Lee SH, Cho EH, Koh EH, Lee WJ, Kim MS, Park JY, Lee KU. Lack of Association between Serum Cystatin C Levels and Coronary Artery Disease in Diabetic Patients. Diabetes Metab J. 2010;34(2):95-100.

Received: Sep 22, 2009; Accepted: Feb 24, 2010

DOI: https://doi.org/10.4093/kdj.2010.34.2.95.

Download citation ↓